Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      I principali esperti europei del cancro alla vescica dichiarano: il test delle urine Bladder EpiCheck di Nucleix può ridurre le procedure invasive


      News provided by

      Nucleix

      Mar 26, 2018, 04:00 ET

      Share this article

      Share this article


      REHOVOT, Israele, March 26, 2018 /PRNewswire/ --

      Bladder EpiCheck™, un nuovo test delle urine, è stato presentato durante il meeting annuale dell'Associazione europea di urologia (EAU), il più importante evento in campo urologico a livello europeo, tenutosi a Copenaghen, in Danimarca.

      Nucleix, un'azienda innovativa operante nel campo della diagnostica e dello screening dei tumori, ha annunciato oggi che il suo primo prodotto Bladder EpiCheck è stato presentato dai principali esperti internazionali del cancro alla vescica in una sessione speciale del meeting dell'EAU. In occasione di queste presentazioni, quattro esperti hanno descritto il test Bladder EpiCheck, i risultati ottenuti in uno studio multicentrico e le modalità in cui può essere utilizzato per ridurre l'onere delle cistoscopie, una procedura invasiva eseguita dagli urologi.

      Il tumore alla vescica è il 5[°] per incidenza in UE ed è caratterizzato da un tasso di recidiva elevato e da un intenso programma di follow-up. Per questi motivi risulta essere il cancro più costoso in base alla durata della vita del paziente e costa all'UE circa 5 miliardi di euro l'anno.

      "Ho partecipato e partecipo a molti studi sui test delle urine, nei quali Bladder EpiCheck ha ottenuto i migliori risultati nel follow-up del cancro alla vescica", ha affermato il prof. Fred Witjes del Radboud University Medical Center di Nijmegen, Paesi Bassi. "Bladder EpiCheck offre a molti pazienti affetti da cancro alla vescica non muscolo-invasivo un'importante possibilità inedita nella fase di follow-up, quando devono sottoporsi a procedure di cistoscopia invasive, e talvolta dolorose, fino a quattro volte l'anno per molti anni. Inoltre, le cistoscopie sottraggono agli ospedali ingenti risorse, quali ad esempio il tempo dedicato da medici e infermieri, denaro, ambienti di cura e attrezzature. Nel complesso, si tratta di una situazione vantaggiosa per pazienti, urologi e per il budget del sistema sanitario".

      "Nel Regno Unito, il Bladder EpiCheck potrebbe svolgere un ruolo significativo contribuendo a ridurre i costi e i tempi di attesa per le cistoscopie di follow-up nei pazienti affetti da cancro alla vescica". Il prof. James Catto dell'Università di Sheffield, Sheffield, Regno Unito, ha dichiarato: "Esiste una chiara esigenza insoddisfatta di una soluzione che sia così orientata al paziente".

      "In seguito al la mia partecipazione a numerosi test sui biomarcatori per la diagnosi del cancro alla vescica e dopo aver eseguito un'analisi indipendente dei risultati delle sperimentazioni multicentriche condotte sul Bladder EpiCheck, è chiaro che questo test ha ottenuto risultati impressionanti nel monitoraggio del cancro alla vescica, con prestazioni che superano i marcatori precedenti in un confronto indiretto.  Il Bladder EpiCheck può fare la differenza nelle nostre decisioni cliniche quotidiane in pazienti affetti da cancro alla vescica non muscolo-invasivo", ha dichiarato il prof. Shahrokh Shariat dell'Università di Medicina di Vienna, Vienna General Hospital, Vienna, Austria. "Nella nostra analisi indipendente abbiamo concluso che, a causa della solidità dei risultati, il suo impatto in termini di utilità clinica può essere sostanziale nei pazienti sottoposti a sorveglianza del cancro alla vescica non muscolo-invasivo."

      "Riteniamo che Bladder EpiCheck possa essere utilizzato per altre finalità tra cui la riduzione delle procedure di ri-resezione della vescica nei pazienti ad alto rischio, e stiamo attualmente valutando il ruolo di Bladder EpiCheck in tale contesto", ha affermato il prof. Roberto Miano dell'Università di Tor Vergata di Roma, Italia. "Con prestazioni così uniche, puntiamo a confermare un numero maggiore di indicazioni per consentire un impiego ancora più ampio di questo test."

      Le presentazioni di questo meeting possono essere visualizzate al link di seguito riportato:

      https://www.youtube.com/watch?v=vioUdjYmGu4

      Informazioni su Nucleix  

      Nucleix sviluppa, produce e commercializza  innovativi test diagnostico-molecolari non invasivi per la diagnosi di tumori. I suoi test, altamente sensibili e specifici, sono basati sull'identificazione di minimi cambiamenti nei pattern di metilazione. La tecnologia di Nucleix è basata sulla combinazione di un nuovo saggio biochimico unito a sofisticati algoritmi.

      Il nostro primo prodotto, il Bladder EpiCheck, è un test che si effettua su campioni di urine per monitorare il cancro alla vescica, e include un pannello di 15 biomarker brevettati. I prodotti di prossima realizzazione sviluppati da Nucleix includono un test di screening sul sangue per la diagnosi precoce del cancro al polmone, grazie al proprio brevetto e alla tecnologia altamente innovativa nel campo dell'epigenetica.

      Nucleix è supportata da OrbiMed e da altri importanti investitori.

      Sito web di Nucleix: http://www.nucleix.com

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.